Jump to content

Apalutamide (Erlyand® in Australia, Erleada® in USA) useful in metastatic castrate-resistant prostate cancer


Recommended Posts

Apalutamide (Erlyand® in Australia, Erleada® in USA) was shown, in a clinical trial called SPARTAN, to be helpful in non-metastatic castrate-resistant prostate cancer. In Australia its use in this way has been approved by the Therapeutic Goods Administration (TGA), and doctors may prescribe it for that purpose.

The vendor has applied to the Pharmaceutical Benefits Advisory Committee (PBAC) to have apalutamide for non-metastatic castrate-resistant prostate cancer put on the PBS, but it is not yet approved.

At the ASCO (American Society of Clinical Oncology) 2019 meeting, Kim N. Chi gave the first report on the TITAN clinical trial of apalutamide for metastatic castrate-resistant prostate cancer.

He reported:

  • A significant improvement in survival with a 33% reduction in the risk of death.
  • A significant improvement in time to evidence of progression on scans.
  • A significant improvement in time to progression to chemotherapy.
  • Tolerability and safety the same as in SPARTAN.
  • Health-related quality of life not different from placebo.

These results will presumably be presented for approval by the FDA in the USA and the TGA in Australia for use in metastatic castrate-resistant prostate cancer

The following article is not on this site.

If you click on the link below, you will be taken to a site where we do not control the content.

So, please be careful about what you read there, and ask your doctor about anything you read.

You may need to subscribe to the site to view the article.

If it is temporarily or permanently unavailable, you may receive an error message.


Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...